{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:09:57Z","timestamp":1790622597420,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002224","name":"Melanoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4583-3","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T20:40:41Z","timestamp":1529613641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines"],"prefix":"10.1186","volume":"18","author":[{"given":"Jingjing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"McMasters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"issue":"7","key":"4583_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396.","journal-title":"Cell"},{"issue":"26","key":"4583_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"9839","key":"4583_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358\u201365.","journal-title":"Lancet"},{"issue":"1","key":"4583_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11912-015-0485-6","volume":"18","author":"RA Johnpulle","year":"2016","unstructured":"Johnpulle RA, Johnson DB, Sosman JA. Molecular targeted therapy approaches for BRAF wild-type melanoma. Curr Oncol Rep. 2016;18(1):6. \n                    https:\/\/doi.org\/10.1007\/s11912-015-0485-6.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"4583_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/j.1755-148X.2009.00630.x","volume":"22","author":"KG Chen","year":"2009","unstructured":"Chen KG, Valencia JC, Gillet JP, Hearing VJ, Gottesman MM. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res. 2009;22(6):740\u20139.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"10","key":"4583_CR6","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1158\/0008-5472.CAN-04-3327","volume":"65","author":"NY Frank","year":"2005","unstructured":"Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65(10):4320\u201333.","journal-title":"Cancer Res"},{"key":"4583_CR7","doi-asserted-by":"publisher","first-page":"47156","DOI":"10.1074\/jbc.M308700200","volume":"278","author":"NY Frank","year":"2003","unstructured":"Frank NY, Pendse SS, Lapchak PH, et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem. 2003;278:47156\u201365.","journal-title":"J Biol Chem"},{"issue":"1","key":"4583_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.18632\/oncotarget.13666","volume":"8","author":"T Gerber","year":"2017","unstructured":"Gerber T, Willscher E, Loeffler-Wirth H, Hopp L, Schadendorf D, Schartl M, Anderegg U, Camp G, Treutlein B, Binder H, Kunz M. Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq. Oncotarget. 2017;8(1):846\u201362.","journal-title":"Oncotarget"},{"issue":"15","key":"4583_CR9","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-11-0221","volume":"71","author":"BJ Wilson","year":"2011","unstructured":"Wilson BJ, Schatton T, Zhan Q, Gasser M, Ma J, Saab KR, Schanche R, Waaga-Gasser AM, Gold JS, Huang Q, Murphy GF, Frank MH, Frank NY. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 2011;71(15):5307\u201316.","journal-title":"Cancer Res"},{"issue":"17","key":"4583_CR10","doi-asserted-by":"publisher","first-page":"13633","DOI":"10.1074\/jbc.M111.308973","volume":"287","author":"AJ Linley","year":"2012","unstructured":"Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SE, Regad T. The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo. J Biol Chem. 2012;287(17):13633\u201343.","journal-title":"J Biol Chem"},{"issue":"5","key":"4583_CR11","doi-asserted-by":"publisher","first-page":"e36762","DOI":"10.1371\/journal.pone.0036762","volume":"7","author":"M Chartrain","year":"2012","unstructured":"Chartrain M, Riond J, Stennevin A, Vandenberghe I, Gomes B, Lamant L, et al. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One. 2012;7(5):e36762.","journal-title":"PLoS One"},{"issue":"1","key":"4583_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1245\/s10434-016-5575-7","volume":"24","author":"H Hao","year":"2017","unstructured":"Hao H, Xiao D, Pan J, Qu J, Egger ME, Waigel S, Sanders MAG, Zacharias W, Rai S, McMasters KM. Sentinel lymph node genes to predict prognosis in node-positive melanoma patients. Ann Surg Oncol. 2017;24(1):108\u201316.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4583_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1089\/humc.2014.022","volume":"25","author":"ME Egger","year":"2014","unstructured":"Egger ME, McNally LR, Nitz J, McMasters KM, Gomez-Gutierrez JG. Adenovirus-mediated FKHRL1\/TM sensitizes melanoma cells to apoptosis induced by temozolomide. Hum Gene Ther Clin Dev. 2014;25(3):186\u201395.","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"318","key":"4583_CR14","doi-asserted-by":"publisher","first-page":"ra30","DOI":"10.1126\/scisignal.2004815","volume":"7","author":"B Sanchez-Laorden","year":"2014","unstructured":"Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C, Marais R. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal. 2014;7(318):ra30.","journal-title":"Sci Signal"},{"key":"4583_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973\u20137.","journal-title":"Nature"},{"key":"4583_CR16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ng.356","volume":"41","author":"D Dankort","year":"2009","unstructured":"Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, Depinho RA, Mcmahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544\u201352.","journal-title":"Nat Genet"},{"key":"4583_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell. 2010;18:683\u201395.","journal-title":"Cancer Cell"},{"issue":"1","key":"4583_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjd.12057","volume":"168","author":"AL Reid","year":"2013","unstructured":"Reid AL, Millward M, Pearce R, Lee M, Frank MH, et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol. 2013;168(1):85\u201392.","journal-title":"Br J Dermatol"},{"issue":"10","key":"4583_CR19","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1038\/jid.2012.161","volume":"132","author":"Y Luo","year":"2012","unstructured":"Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012;132(10):2440\u201350.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"4583_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1158\/1541-7786.MCR-08-0235","volume":"7","author":"AM Elliott","year":"2009","unstructured":"Elliott AM, Al-Hajj MA. ABCB5 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009;7(1):79\u201387.","journal-title":"Mol Cancer Res"},{"issue":"12","key":"4583_CR21","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/0008-5472.CAN-03-3884","volume":"64","author":"Y Huang","year":"2004","unstructured":"Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dia Z, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004;64(12):4292\u2013301.","journal-title":"Cancer Res"},{"issue":"4","key":"4583_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ad.2009.12.006","volume":"101","author":"I V\u00e1squez-Moctezuma","year":"2010","unstructured":"V\u00e1squez-Moctezuma I, Meraz-R\u00edos MA, Villanueva-L\u00f3pez CG, Maga\u00f1a M, Mart\u00ednez-Macias R, S\u00e1nchez-Gonz\u00e1lez DJ, Garc\u00eda-Sierra F, Herrera-Gonz\u00e1lez NE. ATP-binding cassette transporter ABCB5 gene is expressed with variability in malignant melanoma. Actas Dermosifiliogr. 2010;101(4):341\u20138.","journal-title":"Actas Dermosifiliogr"},{"issue":"26","key":"4583_CR23","doi-asserted-by":"publisher","first-page":"9903","DOI":"10.1073\/pnas.0600213103","volume":"103","author":"KG Chen","year":"2006","unstructured":"Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, Berens W, Wincovitch SM, Garfield SH, Leapman RD, Hearing VJ, Gottesman MM. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A. 2006;103(26):9903\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"4583_CR24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/jnci\/djp259","volume":"101","author":"KG Chen","year":"2009","unstructured":"Chen KG, Leapman RD, Zhang G, Lai B, Valencia JC, Cardarelli CO, et al. Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst. 2009;101(18):1259\u201371.","journal-title":"J Natl Cancer Inst"},{"key":"4583_CR25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/1471-2407-10-388","volume":"10","author":"JY Yang","year":"2010","unstructured":"Yang JY, Ha SA, Yang YS, Kim JW. P-glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer. 2010;10:388.","journal-title":"BMC Cancer"},{"issue":"7377","key":"4583_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387\u201390.","journal-title":"Nature"},{"key":"4583_CR27","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/ncomms1727","volume":"3","author":"H Shi","year":"2012","unstructured":"Shi H, et al. Melanoma whole-exome sequencing identifies (V600E) BRAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.","journal-title":"Nat Commun"},{"issue":"48","key":"4583_CR28","doi-asserted-by":"publisher","first-page":"20411","DOI":"10.1073\/pnas.0905833106","volume":"106","author":"CM Emery","year":"2009","unstructured":"Emery CM, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A. 2009;106(48):20411\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4583_CR29","doi-asserted-by":"publisher","first-page":"E536","DOI":"10.1073\/pnas.1418163112","volume":"112","author":"D Perna","year":"2015","unstructured":"Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc Natl Acad Sci U S A. 2015;112(6):E536\u201345.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7408","key":"4583_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson TR, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505\u20139.","journal-title":"Nature"},{"issue":"7408","key":"4583_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500\u20134.","journal-title":"Nature"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4583-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T15:01:02Z","timestamp":1569337262000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4583-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4583"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4583-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"30 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All of the human cell lines used in this study are available from the American Type Culture Collection. Our study is not considered human subjects research because the cells are publicly available, and all the information known about the cell lines is publicly available. Therefore, the use of the cell lines does not require ethics approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"675"}}